You just read:

Capricor Therapeutics Awarded Up to $4.2 Million from National Institutes of Health to Evaluate Exosomes for Hypoplastic Left Heart Syndrome

News provided by

Capricor Therapeutics, Inc.

20 Oct, 2016, 07:00 ET